Work

Low-dose gemcitabine induces major histocompatibility complex class I-related chain A/B expression and enhances an antitumor innate immune response in pancreatic cancer

Year: 2015

Type: article

Source: Clinical and Experimental Medicine

DOI: 10.1007/s10238-015-0394-x

Authors: Tomoharu Miyashita, Kenji Miki, Takashi Kamigaki, Isamu Makino, Hisatoshi Nakagawara, Hidehiro Tajima, Hiroyuki Takamura, Hirohisa Kitagawa, Sachio Fushida, Ali K. Ahmed, Mark D. Duncan, John W. Harmon, Tetsuo Ohta

Institutions: Kanazawa University Hospital, Medinet Co., Ltd. (Japan), Johns Hopkins University, Johns Hopkins Medicine

Language: English

Topic: Immune Cell Function and Interaction

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Japan Society for the Promotion of Science

Awards: Study of suppression of fibrosis and EMT in pancreatic cancer radiation therapy, Investigation of biological basis of GSK3beta-targeted therapy and its translation to colorectal cancer treatment, Low-dose gemcitabine induces major histocompatibility complex class I-related chain A/B expression and enhances an antitumor innate immune response in pancreatic cancer.

OpenAlex ID: W1942341004

FWCI: 0.984

Cites: 48

Cited by: 27

Related to: 10